Open-Label Randomized Trial of Early Clinical Outcomes of Ceftaroline Fosamil Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections at Risk of Methicillin-Resistant Staphylococcus aureus

[1]  G. Escobar,et al.  The Timing of Early Antibiotics and Hospital Mortality in Sepsis , 2017, American journal of respiratory and critical care medicine.

[2]  D. Nathwani,et al.  Early Clinical Response as a Predictor of Late Treatment Success in Patients With Acute Bacterial Skin and Skin Structure Infections: Retrospective Analysis of 2 Randomized Controlled Trials , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  D. Nathwani,et al.  Early clinical assessment of response to treatment of skin and soft-tissue infections: how can it help clinicians? Perspectives from Europe. , 2016, International journal of antimicrobial agents.

[4]  S. Skrede,et al.  Early Response in Cellulitis: A Prospective Study of Dynamics and Predictors , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  K. Kaye,et al.  Rising United States Hospital Admissions for Acute Bacterial Skin and Skin Structure Infections: Recent Trends and Economic Impact , 2015, PloS one.

[6]  G. Corey,et al.  An open-label, pragmatic, randomized controlled clinical trial to evaluate the comparative effectiveness of daptomycin versus vancomycin for the treatment of complicated skin and skin structure infection , 2015, BMC Infectious Diseases.

[7]  Hien H. Nguyen,et al.  Acute bacterial skin and skin structure infections (ABSSSI): practice guidelines for management and care transitions in the emergency department and hospital. , 2015, The Journal of emergency medicine.

[8]  E. P. Dellinger,et al.  Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  Jan V Hirschmann,et al.  Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  K. Itani,et al.  Outcomes and management costs in patients hospitalized for skin and skin-structure infections. , 2011, American journal of infection control.

[11]  M. Dryden.  Complicated skin and soft tissue infection. , 2010, The Journal of antimicrobial chemotherapy.

[12]  F. Trautinger,et al.  CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. , 2010, The Journal of antimicrobial chemotherapy.

[13]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.

[14]  K. Chapin,et al.  Rapid Detection of Staphylococcus aureus and Methicillin-Resistant S. aureus (MRSA) in Wound Specimens and Blood Cultures: Multicenter Preclinical Evaluation of the Cepheid Xpert MRSA/SA Skin and Soft Tissue and Blood Culture Assays , 2009, Journal of Clinical Microbiology.

[15]  J. Maselli,et al.  National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. , 2008, Archives of internal medicine.

[16]  M. Rybak,et al.  Daptomycin versus Vancomycin for Complicated Skin and Skin Structure Infections: Clinical and Economic Outcomes , 2007, Pharmacotherapy.

[17]  G. Oster,et al.  Trends in US Hospital Admissions for Skin and Soft Tissue Infections , 2007, Emerging infectious diseases.

[18]  Patchen Dellinger,et al.  Practice guidelines for the diagnosis and management of skin and soft-tissue infections. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  Or.  Non-Inferiority Clinical Trials to Establish Effectiveness Guidance for Industry , 2016 .

[20]  M. Wilcox,et al.  CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. , 2010, The Journal of antimicrobial chemotherapy.